First Trust Direct Indexing’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,895
| Closed | -$521K | – | 41 |
|
|
2024
Q3 | $521K | Sell |
1,895
-1,047
| -36% | -$288K | 0.03% | 533 |
|
|
2024
Q2 | $715K | Buy |
2,942
+286
| +11% | +$69.5K | 0.04% | 408 |
|
|
2024
Q1 | $397K | Sell |
2,656
-242
| -8% | -$36.2K | 0.03% | 537 |
|
|
2023
Q4 | $555K | Buy |
2,898
+340
| +13% | +$65.1K | 0.05% | 418 |
|
|
2023
Q3 | $453K | Buy |
2,558
+187
| +8% | +$33.1K | 0.05% | 421 |
|
|
2023
Q2 | $450K | Buy |
2,371
+84
| +4% | +$16K | 0.05% | 439 |
|
|
2023
Q1 | $458K | Sell |
2,287
-183
| -7% | -$36.7K | 0.05% | 429 |
|
|
2022
Q4 | $587K | Buy |
2,470
+271
| +12% | +$64.4K | 0.08% | 334 |
|
|
2022
Q3 | $440K | Sell |
2,199
-181
| -8% | -$36.2K | 0.06% | 374 |
|
|
2022
Q2 | $347K | Sell |
2,380
-517
| -18% | -$75.4K | 0.05% | 431 |
|
|
2022
Q1 | $473K | Buy |
2,897
+710
| +32% | +$116K | 0.06% | 385 |
|
|
2021
Q4 | $371K | Buy |
2,187
+87
| +4% | +$14.8K | 0.05% | 438 |
|
|
2021
Q3 | $397K | Buy |
2,100
+159
| +8% | +$30.1K | 0.06% | 401 |
|
|
2021
Q2 | $329K | Sell |
1,941
-190
| -9% | -$32.2K | 0.05% | 441 |
|
|
2021
Q1 | $301K | Hold |
2,131
| – | – | 0.08% | 310 |
|
|
2020
Q4 | $277K | Buy |
+2,131
| New | +$277K | 0.07% | 299 |
|